WAVE Life Sciences Ltd. (WVE) Analysts See $-1.00 EPS

February 15, 2018 - By Nellie Frank

 WAVE Life Sciences Ltd. (WVE) Analysts See $ 1.00 EPS

Analysts expect WAVE Life Sciences Ltd. (NASDAQ:WVE) to report $-1.00 EPS on March, 15.They anticipate $0.21 EPS change or 26.58 % from last quarter’s $-0.79 EPS. After having $-0.94 EPS previously, WAVE Life Sciences Ltd.’s analysts see 6.38 % EPS growth. The stock increased 8.22% or $3.98 during the last trading session, reaching $52.33. About 313,636 shares traded or 60.07% up from the average. WAVE Life Sciences Ltd. (NASDAQ:WVE) has risen 36.01% since February 15, 2017 and is uptrending. It has outperformed by 19.31% the S&P500.

WAVE Life Sciences Ltd. (NASDAQ:WVE) Ratings Coverage

Among 5 analysts covering WAVE Life Sciences (NASDAQ:WVE), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. WAVE Life Sciences had 5 analyst reports since December 7, 2015 according to SRatingsIntel. The rating was initiated by Jefferies with “Buy” on Monday, December 7. As per Monday, December 7, the company rating was initiated by Leerink Swann. JMP Securities initiated the stock with “Mkt Outperform” rating in Monday, December 7 report. SunTrust initiated the shares of WVE in report on Monday, December 7 with “Buy” rating. Suntrust Robinson initiated WAVE Life Sciences Ltd. (NASDAQ:WVE) on Monday, December 7 with “Buy” rating.

WAVE Life Sciences Ltd., a genetic medicines company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company has market cap of $1.45 billion. The firm is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It currently has negative earnings. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system.

More notable recent WAVE Life Sciences Ltd. (NASDAQ:WVE) news were published by: Fool.com which released: “Here’s Why Wave Life Sciences Fell as Much as 12.1% This Morning” on April 12, 2017, also Businesswire.com with their article: “Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 …” published on July 17, 2017, Businesswire.com published: “Wave Life Sciences Unveils New Manufacturing Facility in Lexington, MA” on October 26, 2017. More interesting news about WAVE Life Sciences Ltd. (NASDAQ:WVE) were released by: Businesswire.com and their article: “Wave Life Sciences Initiates Clinical Trial for Lead Program in Duchenne …” published on November 06, 2017 as well as Businesswire.com‘s news article titled: “Wave Life Sciences Reports Third Quarter 2017 Financial Results and Provides …” with publication date: November 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.